HealthQuill Inflammatory Bowel Disease
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor to treat inflammatory bowel disease.
Drugs Health Pharma

Eli Lilly to buy Morphic for $3.2 b in cash to expand integrin therapies

Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.

Read More
Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s disease in adults, have failed to meet the goal of clinical remission.
Drugs Health Pharma

Bristol’s oral drug to treat Crohn’s disease fails remission test

HQ Team March 29, 2024: Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s.

Read More
AstraZeneca, a British-Swedish pharmaceutical company, has signed a deal, worth more than $2 billion, with Quell Therapeutics to develop cell therapies for treating autoimmune diseases.
Drugs Health Pharma

AstraZeneca signs $2 billion deal for autoimmune diseases

HQ Team June 9, 2023: AstraZeneca, a British-Swedish pharmaceutical company, has signed a deal, worth more than $2 billion, with Quell Therapeutics to.

Read More
X